

2024 Step Therapy Criteria

Updated 10/15/2023

HMG-COA INHIBITORS

Products Affected

Step 1:

- amlodipine 10 mg-atorvastatin 10 mg tablet
- amlodipine 10 mg-atorvastatin 20 mg tablet
- amlodipine 10 mg-atorvastatin 40 mg tablet
- amlodipine 10 mg-atorvastatin 80 mg tablet
- amlodipine 2.5 mg-atorvastatin 10 mg tablet
- amlodipine 2.5 mg-atorvastatin 20 mg tablet
- amlodipine 2.5 mg-atorvastatin 40 mg tablet
- amlodipine 5 mg-atorvastatin 10 mg tablet
- amlodipine 5 mg-atorvastatin 20 mg tablet
- amlodipine 5 mg-atorvastatin 40 mg tablet
- amlodipine 5 mg-atorvastatin 80 mg tablet
- atorvastatin 10 mg tablet
- atorvastatin 20 mg tablet
- atorvastatin 40 mg tablet
- atorvastatin 80 mg tablet
- ezetimibe 10 mg-simvastatin 10 mg tablet
- ezetimibe 10 mg-simvastatin 20 mg tablet
- ezetimibe 10 mg-simvastatin 40 mg tablet
- ezetimibe 10 mg-simvastatin 80 mg tablet
- fluvastatin 20 mg capsule
- fluvastatin 40 mg capsule
- fluvastatin ER 80 mg tablet, extended release 24 hr
- lovastatin 10 mg tablet
- lovastatin 20 mg tablet
- lovastatin 40 mg tablet
- pravastatin 10 mg tablet
- pravastatin 20 mg tablet
- pravastatin 40 mg tablet
- pravastatin 80 mg tablet
- rosuvastatin 10 mg tablet
- rosuvastatin 20 mg tablet
- rosuvastatin 40 mg tablet
- rosuvastatin 5 mg tablet
- simvastatin 10 mg tablet
- simvastatin 20 mg tablet
- simvastatin 40 mg tablet
- simvastatin 5 mg tablet
- simvastatin 80 mg tablet

Step 2:

- Ezallor Sprinkle 10 mg capsule
- Ezallor Sprinkle 20 mg capsule
- Ezallor Sprinkle 40 mg capsule
- Ezallor Sprinkle 5 mg capsule
- Zypitamag 2 mg tablet
- Zypitamag 4 mg tablet

Details

Criteria	Coverage will be provided if atorvastatin, ezetimibe/simvastatin, fluvastatin, fluvastatin extended-release, lovastatin, pravastatin, rosuvastatin tablets, simvastatin tablets, or amlodipine/atorvastatin has been tried (at least a 30-day supply in the prior 180 days).
-----------------	--

ORAL BISPHOSPHONATES

Products Affected

Step 1:

- alendronate 10 mg tablet
- alendronate 35 mg tablet
- alendronate 70 mg tablet
- alendronate 70 mg/75 mL oral solution
- ibandronate 150 mg tablet
- risedronate 150 mg tablet
- risedronate 30 mg tablet
- risedronate 35 mg tablet
- risedronate 35 mg tablet (12 pack)
- risedronate 35 mg tablet (4 pack)
- risedronate 35 mg tablet, delayed release
- risedronate 5 mg tablet

Step 2:

- Fosamax Plus D 70 mg-2,800 unit tablet
- Fosamax Plus D 70 mg-5,600 unit tablet

Details

Criteria	Coverage will be provided if two Step 1 drugs have been tried (at least a 1-day supply in the prior 180 days).
----------	--

URINARY ANTISPASMODICS

Products Affected

Step 1:

- fesoterodine ER 4 mg tablet, extended release 24 hr
- fesoterodine ER 8 mg tablet, extended release 24 hr
- Gemtesa 75 mg tablet
- Myrbetriq 25 mg tablet, extended release
- Myrbetriq 50 mg tablet, extended release
- Myrbetriq 8 mg/mL oral suspension, extended release
- oxybutynin chloride 5 mg tablet
- oxybutynin chloride 5 mg/5 mL oral syrup
- oxybutynin chloride ER 10 mg tablet, extended release 24 hr
- oxybutynin chloride ER 15 mg tablet, extended release 24 hr
- oxybutynin chloride ER 5 mg tablet, extended release 24 hr
- solifenacin 10 mg tablet
- solifenacin 5 mg tablet
- tolterodine 1 mg tablet
- tolterodine 2 mg tablet
- trospium 20 mg tablet

Step 2:

- darifenacin ER 15 mg tablet, extended release 24 hr
- darifenacin ER 7.5 mg tablet, extended release 24 hr
- tolterodine ER 2 mg capsule, extended release 24 hr
- tolterodine ER 4 mg capsule, extended release 24 hr

Details

Criteria	Coverage will be provided if fesoterodine, mirabegron, oxybutynin, oxybutynin extended-release, solifenacin tablets, tolterodine tablets, trospium immediate-release, or vibegron has been tried (at least a 30-day supply in the prior 180 days).
-----------------	--